Form 4: Alnylam CCO's Stock Vesting & Tax Sales

Alnylam Pharmaceuticals' Chief Commercial Officer, Tolga Tanguler, reported the vesting of performance-based stock units and subsequent sale of shares to cover tax obligations.

Summary

• Tolga Tanguler, EVP, Chief Commercial Officer of Alnylam Pharmaceuticals, Inc. (ALNY), reported changes in his beneficial ownership of company common stock.
• On August 15, 2025, 2,851 shares of common stock were acquired due to the vesting of performance-based stock units (PSUs).
• The PSU vesting was based on the achievement of a clinical milestone, as determined by the Issuer's People, Culture and Compensation Committee.
• On August 18, 2025, a total of 1,396 shares of common stock were sold in multiple transactions.
• These sales were mandatory 'sell-to-cover' transactions to satisfy minimum statutory tax withholding obligations upon the vesting and settlement of restricted stock units (RSUs) granted on March 1, 2024.
• The sales occurred at weighted average prices ranging from $447.98 to $455.82 per share.
• Following these transactions, the reporting person beneficially owns 29,466 shares of common stock directly.

Sentiment

Score: 5

Explanation: The filing is neutral. It reports routine insider transactions related to executive compensation (vesting of PSUs due to a clinical milestone and subsequent sell-to-cover for taxes). It does not provide new operational or financial performance data that would significantly alter the company's outlook.

Positives

• The vesting of 2,851 performance-based stock units (PSUs) indicates the achievement of a specified clinical milestone, reflecting progress in Alnylam's pipeline or development efforts.

Negatives

• The reported sales of 1,396 shares were mandatory 'sell-to-cover' transactions for tax withholding purposes, not discretionary sales, and therefore do not indicate a negative outlook from the insider.

Future Outlook

This filing is a routine insider transaction report and does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Management Comments

• The People, Culture and Compensation Committee of the Issuer Board of Directors determined the achievement of a clinical milestone, leading to the vesting of performance-based stock units.

Industry Context

This Form 4 filing is a standard disclosure of insider stock transactions, common across all publicly traded companies. It reflects executive compensation events rather than operational or strategic shifts within the biotechnology and pharmaceutical industry.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine compensation-related transactions and not discretionary sales indicating a change in management's confidence. The vesting of PSUs due to a clinical milestone could be seen as a positive for long-term value creation.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of performance-based stock units due to a clinical milestone and subsequent mandatory sales to cover tax obligations. It does not contain new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals and market conditions, as this filing provides no new catalysts for a 'buy' or 'sell' decision.

Keywords

Alnylam Pharmaceuticals, ALNY, Form 4, Insider Transaction, Stock Vesting, Performance Stock Units, Restricted Stock Units, Executive Compensation, Biotechnology, Pharmaceuticals